-
公开(公告)号：EP3091019A2
公开(公告)日：2016-11-09
申请号：EP16171952.1
申请日：2010-10-07
发明人： CHIOSIS, Gabriela , TALDONE, Tony , SUN, Weilin
IPC分类号： C07D473/34 , A61K31/538 , A61K31/52 , A61P25/00 , A61P25/28 , A61P35/00
CPC分类号： A61K31/52 , A61K31/538 , C07D473/34
摘要： The present application provides substituted purine derivatives (I) and related compounds of the formulas shown. These compounds are useful as inhibitors of HSP90, and hence in the treatment of related diseases. (Formulae) Z 1 -Z 3 , X a -X c , X 2 , X 4 , Y and R are as defined in the specification.
摘要翻译： 本申请提供了取代的嘌呤衍生物（I）和所示式的相关化合物。 这些化合物可用作HSP90的抑制剂，因此可用于治疗相关疾病。 （式）Z1-Z3，Xa-Xc，X2，X4，Y和R如说明书中所定义。
-
12.发明公开METHODS AND COMPOSITIONS FOR IMAGING DISORDERS USING POLYSPECIFIC AGENTS 审中-公开方法和组合物PICTURE与多特异性的，资金的疾病
公开(公告)号：EP3046468A1
公开(公告)日：2016-07-27
申请号：EP14845358.2
申请日：2014-09-18
IPC分类号： A61B5/055
CPC分类号： A61K51/1075 , A61B5/055
摘要： The present invention provides compositions and methods for detecting and/or monitoring a disease state with polyspecific imaging agents. In a particular embodiment, provided methods may be used to assess efficacy of anti-receptor tyrosine kinase and/or anti-cancer treatments. In some embodiments, the present invention provides methods and compositions relating to polyspecific imaging agents that target neurological, tumor-associated and/or intratumoral markers. For example, the present invention provides compositions, including pharmaceutical compositions, comprising anti-receptor tyrosine kinase antibodies, or fragments or characteristic portions thereof. The present invention further provides various therapeutic and/or diagnostic methods of using anti-receptor tyrosine kinase antibodies and/or compositions.
-
公开(公告)号：EP2943155A2
公开(公告)日：2015-11-18
申请号：EP14738194.1
申请日：2014-01-08
发明人： ABRAMSON, David , BOHLE, George C. , FRISCH, Paul , MARR, Brian P. , BOOTH, Paul , BLACK, Phillip C. , KATZE, Alan B. , MOORE, James G.
IPC分类号： A61F2/14
CPC分类号： A61F2/141 , A61B5/11 , A61B5/6821 , A61B2560/0223 , A61B2562/0219 , A61B2562/0223 , A61B2562/046 , A61F2002/482 , A61F2230/0019 , A61F2250/0096 , A61F2250/0097
摘要： An ocular prosthesis includes a display device visible at an anterior portion of the ocular prosthesis. The display device is configured to present a changeable image that represents a natural appearance and movement for a visible portion of an eyeball of a subject. A system includes, besides the ocular prosthesis, an implant marker configured to move with an orbital implant disposed in an eye socket of a subject. A method includes determining a change in orientation of an orbital implant in a subject and determining an update to a natural appearance for a visible portion of an eyeball for the subject based on the change in orientation of the orbital implant. The method also includes rendering an update to an image of the natural appearance for a display device disposed in an ocular prosthesis configured to be inserted in the subject anterior to the orbital implant.
-
公开(公告)号：EP2010556B1
公开(公告)日：2015-09-23
申请号：EP07755136.4
申请日：2007-04-11
发明人： DANISHEFSKY, Samuel J. , WARREN, J. David , CHEN, Jiehao , WU, Bin , CHEN, Gong , WAN, Qian , TAN, Zhongping , KAN, Cindy , YUAN, Yu , HUA, Zihao , RANGANATHAN, Krishnakumar , TRZUPEK, John D.
IPC分类号： C07K14/505 , A61K38/16
CPC分类号： C07K14/505 , C07K9/00 , C12P21/005
-
公开(公告)号：EP2854850A2
公开(公告)日：2015-04-08
申请号：EP13793069.9
申请日：2013-05-28
发明人： KOLESNICK, Richard , ROTOLO, Jimmy
CPC分类号： A61K39/39533 , A61K31/4709 , A61K31/496 , A61K31/55 , A61K39/39541 , A61K45/06 , C07K16/18 , C07K16/44 , C07K2317/24 , C07K2317/76 , A61K2300/00
摘要： It has been discovered that administering therapeutically effective amounts of an antibiotic that kills Gram-negative bacteria, together with an anti-ceramide antibody or anti-ceramide mimetic, treats and prevents an array of diseases mediated by cytolytic T lymphocyte (CTL)-induced killing and/or by damage to endothelial microvasculature, including Radiation GI syndrome, GvHD disease, inflammatory diseases and autoimmune diseases.
-
公开(公告)号：EP2831593A1
公开(公告)日：2015-02-04
申请号：EP13770052.2
申请日：2013-03-15
发明人： MASSAGUE, Joan , ACHARYYA, Swarnali
IPC分类号： G01N33/574 , G01N33/68 , G01N33/48
CPC分类号： C12Q1/6886 , C12Q2600/136 , G01N33/57415 , G01N33/57423 , G01N2800/52
摘要： Determinations of the level of expression of S100A8/A9 protein serve as a prognostic indicator of the therapeutic response to a given type of chemotherapy treatment and as a monitoring indicator of the effectiveness of an on-going chemotherapy treatment for the treatment of breast cancer in human patients. Kits can be used for performing these determinations.
-
17.发明公开PREDICTION OF RESPONSIVENESS TO TREATMENT WITH IMMUNOMODULATORY THERAPEUTICS AND METHOD OF MONITORING ABSCOPAL EFFECTS DURING SUCH TREATMENT 有权预测对，以监控ABSKOPAL效应在这个过程中的免疫调节治疗剂和方法的治疗反应
公开(公告)号：EP2817619A1
公开(公告)日：2014-12-31
申请号：EP13752111.8
申请日：2013-02-22
IPC分类号： G01N33/49 , G01N33/68 , A61K39/395 , A61P35/00
CPC分类号： G01N33/57492 , A61K2039/505 , C07K16/2818 , G01N33/5011 , G01N2333/70503 , G01N2800/52
摘要： Efficacy of a therapeutic to enhance antitumor immunity in a patient is predicted, where the therapeutic is one that targets an immunomodulatory leukocyte membrane protein (ILMP) to enhance immune activity. Peripheral blood sample from the patient is tested for levels of monocytes having specific cell surface markers (CD14
+ , HLA-DR
low ) prior to treatment. Low levels of monocytes of this type (PBM14
+ HLA-DR
low ) indicate a greater likelihood of therapeutic efficacy. In specific exemplary embodiments of the invention, the therapeutic is an antibody to CTLA4, such as ipilimumab or tremelimumab.-
18.发明授权WT1 HLA class II-binding peptides and compositions and methods comprising same 有权WT1-HLA II类结合肽，以及组合物和方法因此
公开(公告)号：EP2565201B1
公开(公告)日：2014-11-26
申请号：EP12172030.4
申请日：2006-10-17
CPC分类号： C07K14/4748 , A61K38/00 , A61K39/00 , A61K39/0011 , A61K2039/5158 , A61K2039/57
-
公开(公告)号：EP1487426B1
公开(公告)日：2012-08-22
申请号：EP03711372.7
申请日：2003-03-04
CPC分类号： A61K9/4866 , A61K9/0019 , A61K9/1652 , A61K31/13 , A61K31/164 , A61K31/165 , A61K31/19 , A61K31/44 , A61K38/12 , A61K47/12 , A61K47/38
摘要： The present invention provides methods of selectively inducing terminal differentiation, cell growth arrest and/or apoptosis of neoplastic cells, and/or inhibiting histone deacetylase (HDAC) by administration of pharmaceutical compositions comprising potent HDAC inhibitors. The oral bioavailability of the active compounds in the pharmaceutical compositions of the present invention is surprisingly high. Moreover, the pharmaceutical compositions unexpectedly give rise to high, therapeutically effective blood levels of the active compounds over an extended period of time. The present invention further provides a safe, daily dosing regimen of these pharmaceutical compositions, which is easy to follow, and which results in a therapeutically effective amount of the HDAC inhibitors in vivo.
-
公开(公告)号：EP2281897A3
公开(公告)日：2011-11-30
申请号：EP10186056.7
申请日：2004-11-17
发明人： Brown, Susanne Moira , Dunn, Paul , Singh, Bhuvanesh , Ganly, Ian
IPC分类号： C12N15/869 , A61K35/76 , C12N7/01 , C07K14/82 , C12N15/113 , A61K48/00
CPC分类号： C12N15/1135 , A01K2267/0331 , A61K35/13 , A61K48/00 , A61K2039/5256 , C12N7/00 , C12N15/86 , C12N2710/16643 , C12N2840/203 , Y02A50/473
摘要： An herpes simplex virus wherein the herpes simplex virus genome comprises nucleic acid encoding an antisense to the squamous cell carcinoma related oncogene (asSCCRO); and an herpes simplex virus wherein the herpes simplex virus genome comprises nucleic acid encoding a short interfering ribonucleic acid (siRNA) molecule that is capable of repressing or silencing expression of squamous cell carcinoma related oncogene (SCCRO) nucleic acid or polypeptide are disclosed together with methods for generation and applications of such viruses.
-
-
-
-
-
-
-
-
-
搜索结果
439 条记录 (耗时 0.051 秒)
